Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar by Andriamanantena, Tahiry S et al.
Andriamanantena et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:17
http://www.ann-clinmicrob.com/content/9/1/17
Open Access RESEARCH
© 2010 Andriamanantena et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Research Dissemination of multidrug resistant Acinetobacter 
baumannii in various hospitals of Antananarivo 
Madagascar
Tahiry S Andriamanantena1, Elisoa Ratsima1, Hanitra C Rakotonirina1, Frédérique Randrianirina1, Lovasoa Ramparany1, 
Jean-François Carod1, Vincent Richard1 and Antoine Talarmin*1,2
Abstract
This study reports the dissemination of multidrug-resistant (MDR) OXA-23-producing Acinetobacter baumannii clones 
in hospitals in Antananarivo, Madagascar. A total of 53 carbapenem-resistant A. baumannii isolates were obtained from 
September 2006 to March 2009 in five hospitals. These resistant strains represent 44% of all A. baumannii isolates. The 
double disk synergy test was performed to screen for production of metallo-beta-lactamases. Polymerase chain 
reaction (PCR) and DNA sequencing were performed for the detection of bla(AmpC), bla(OXA-51),bla(OXA-23), 
bla(OXA-24), bla(IMP), bla(VIM). The presence of the insertion sequence ISAba1 relative to blaOXA-23 and blaOXA-51 
was assessed by PCR. Isolates were typed by Rep-PCR. All the isolates were MDR and produced the OXA-23 
carbapenemase, which was confirmed by sequencing. PCR analysis for AmpC and OXA-51 gave positive results for all 
strains studied. No isolates produced metallo-beta-lactamases. In all isolates ISAba1 laid upstream of blaOXA-23. The A. 
baumannii isolates were separated into two genotypes; genotype A had a higher prevalence (41 strains) than 
genotype B (12 strains). Genotype A was present in four hospitals, whilst genotype B had spread in two hospitals. The 
high frequency of MDR OXA-23-producing A. baumannii in various hospitals in Antananarivo is curious since 
carbapenems are not available in Madagascar, but it emphasises the need for infection control procedures and strict 
adherence to them to prevent the spread of these resistant organisms in Antananarivo and also the need to control the 
use of carbapenems in the future.
1. Introduction
Acinetobacter baumannii is an agent of nosocomial infec-
t i o n s,  e s pec ia l l y  p n e u m o n ia.  I t  is  fr eq u e n t l y  as s oci a t ed
with nosocomial outbreaks worldwide [1,2]. Immuno-
compromised patients have a high risk of being infected
with this organism. A. baumannii has become particu-
larly problematic worldwide because of its resistance pat-
terns. Hospital strains of A. baumannii are usually
multidrug resistant. The problem is aggravated by
increasing resistance to broad-spectrum antibiotics
including carbapenems, the drugs of choice for hospital-
acquired A. baumannii infections [3-5].
Indeed, carbapenems are generally the last resort in the
treatment of lifethreatening infections caused by Acineto-
bacter spp. because they are not affected by most β-lacta-
mases, including extended-spectrum β-lactamases.
However their efficacy is increasingly compromised by
the emergence of carbapenem-hydrolysing β -lactamase
enzymes of Ambler molecular class B (metallo- β-lacta-
mases) and D (oxacillinases) [3,6]. Metalloenzymes are
prevalent in East Asia but the OXA-type carbapenemases
have emerged as the main mechanism responsible for this
resistance worldwide. Recently, the number of OXA-type
carbapenemases has increased and they have been
divided into eight subgroups of enzymes; four of them
have been identified in A. baumannii: OXA-23-like
(OXA-23, OXA-27 and OXA-49); OXA-24-like (OXA-24,
OXA-25, OXA-26, OXA-40 and OXA-72); OXA-58; and
OXA-51-like. The last group constitutes a family of chro-
mosomal enzymes typically present in A. baumannii [7].
Outbreaks of OXA-23-producing Acinetobacter  have
been reported from various regions of the world [8-13].
During a study on hospital-acquired infections con-
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ducted in various surgical units located in two hospitals
of Antananarivo, the capital city of Madagascar, A. bau-
mannii  represented 9.4% of all pathogens isolated.
Among them, 44% were resistant to imipenem although
carbapenems are not available in Madagascar [14]. We
determined the resistance mechanisms of A. baumannii
to imipenem in Antananarivo and attempted to explain
the dissemination of these strains.
2. Material and methods
2.1. Bacterial isolates
From September 2006 to March 2009, 53 non repetitive
clinical isolates of imipenem non-susceptible A. bauman-
nii, based on the results of disk diffusion tests, were col-
lected from 53 patients from four hospitals (three public
and one private) in Antananarivo, Madagascar. Bacterial
isolates were obtained from skin wounds (54.6%), urine
(18.9%), respiratory tract secretions (15.1%), blood (5.7%)
and other sites (5.7%). Most of the isolates were obtained
from patients admitted to the Soavinandriana (HOMI)
(45.3%) or Ravoangy Andrianavaolona (HJRA) (39.6%)
hospitals. Five control strains obtained at the same time
from other patients at two of the hospitals studied and
susceptible to carbapenems, with minimum inhibitory
concentrations (MICs) of 0.5-2 μg/ml for imipenem were
used.
Isolates were identified by conventional techniques.
They were kept frozen at -20°C in skimmed milk until
further testing.
2.2. Antimicrobial susceptibility testing
The disk diffusion method was used to assess susceptibil-
ity to the following antimicrobial agents: amikacin;
tobramicin; gentamycin; ticarcillin/clavulanic acid; piper-
acillin/tazobactam; ceftazidime; ampicillin/sulbactam;
ciprofloxacin; sulfamethoxazole/trimethoprim, imi-
penem and colistin. MIC values of imipenem were deter-
mined using agar plate dilution. Two-fold serial dilutions
of imipenem were added to molten Mueller-Hinton agar
base (Oxoid) at a temperature of 45°C. The resulting
plates were seeded with 104 cfu/spot of bacteria by means
of a multipoint inoculator and incubated at 37°C for 24 h.
Escherichia coli ATCC 25922 and Pseudomonas aerugi-
nosa ATCC 27853 were used as controls and included in
each run. The imipenem concentration range was from
0.5 to 512 μg/ml. MIC values of meropenem were deter-
mined by Etest (BioMérieux, Marcy l'Etoile, France)
according to the manufacturer's instructions. The mero-
penem concentration range from 0.02 to 32 μg/ml. Anti-
microbial susceptibility was scored using breakpoint
criteria shown in table 1 as defined by the Antibiogram
Committee of the French Microbiology Society (CASFM)
[15], except for ampicilin/sulbactam for which we used
the criteria of the Clinical and Laboratory Standards
Institute [16].
Carbapenem-resistant  A. baumannii (CRAB) isolates
were screened by the modified Hodge test, to evaluate the
inactivation of imipenem by carbapenemases, [17].
All strains were tested for the presence of metallo-
enzymes using the imipenem-EDTA double-disk synergy
test [17].
2.3. PCR amplification and sequencing
DNA was extracted from the isolates by boiling five colo-
nies in 250 μl of sterile ultrapure water for 10 minutes,
followed by cooling in ice for 10 minutes and centrifuga-
tion for 1 min at 14,000 rpm. Supernatants were con-
served at -20°C until amplification. Genes coding for class
B and D carbapenemases were sought by PCR using Taq
polymerase with specific primers. Attempts were made to
detect and map the presence of ISAba1  relative to
blaOXA-23 and blaOXA-51 using the primer pairs
ISAba1F/OXA-23-seqR (expected size 1456 bp) and
ISAba1F/OXA-51-R (expected size 1223 bp), respectively.
All primers used are listed in table 2.
The amplified products were observed after electro-
phoresis on a 1% agarose gel with ethidium bromide
staining; purified, amplified products were then
sequenced with the dye termination cycle sequencing
technique (Genome Express Company, Meylan, France).
Searches and alignments for the nucleotide sequences
were performed with the BLAST program http://
www.ncbi.nlm.nih.gov/BLAST.
2.4. REP-PCR
REP-PCR, which uses consensus primers for the REP
sequences found in many bacterial chromosomes, was
used in the genotyping of A. baumannii clones [23,24].
This highly conserved REP sequence is approximately 35
nucleotides long, includes an inverted repeat, and can
occur in the genome singly or as multiple adjacent copies.
The primer pair REP 1 (5'-IIIGCGCCGICATCAGGC-3')
and REP 2 (5'-ACGTCTTATCAGGCCTAC-3') was used
to amplify putative REP-like elements in the bacterial
DNA. Amplification PCRs were performed as described
previously [23,24]. A negative control to detect reagent
contamination was included in each PCR, containing all
components except the DNA extract, which was replaced
by 5 μl of sterile distilled H2O. Aliquots (12 μl) of each
sample were subjected to electrophoresis in a 1.5% aga-
rose gel. Amplified products were detected by staining
with ethidium bromide and photographed with Polaroid
type 665 film.
To group isolates for photographic documentation, the
REP-PCR fingerprints of strains were exposed to UV
light, photographed, and compared by visual inspection.Andriamanantena et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:17
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The molecular sizes of fragments generated by electro-
phoresis were estimated from comparisons with relative
molecular mass standards run concurrently. Fingerprints
w e r e  c o n s i d e r e d  t o  b e  h i g h l y  s i m i l a r  w h e n  a l l  v i s i b l e
bands from the two isolates had the same apparent
migration distance. Variations in the intensity or shape of
bands were not taken into account. The absence of up to
two bands from a fingerprint was allowed, when all other
visible bands in the fingerprints matched, before isolates
were considered to be different by visual inspection
[23,24]. Each isolate was run in duplicate. Fingerprint
profiles were interpreted with no knowledge of the clini-
cal data.
3. Results
According to the results of the antimicrobial susceptibil-
ity testing by disk diffusion for 53 imipenem non-suscep-
tible A. baumannii isolates, all isolates were resistant to
most of the antimicrobials tested. Apart from colistin to
which all isolates were susceptible, the highest rates of
susceptibility were observed with ampicillin/sulbactam
(79.2%; n = 42), tobramycin (67.9%; n = 36) and amikacin
(47,2%; n = 25) (Table 1). According to the results of
MICs, one isolate was intermediate and all isolates were
resistant to imipenem and to meropenem. The MIC of
imipenem varied slightly; for 13 isolates it was 16 μg/ml,
for 39 isolates it was 32 μg/ml whereas for one strain it
was 64 μg/ml. All strains had MICs ≥ 32 μg/ml to mero-
penem. No synergy was observed using the imipenem-
EDTA double-disk synergy test. Using the modified
Hodge test, the presence of carbapenemases was detected
in 46 (86,8%) of the CRAB consistent with PCR results.
Indeed, using PCR and DNA sequencing of the PCR
product, all 53 CRAB isolates showed the presence of
blaOXA-23 and blaOXA-51 but none had blaOXA-24-
like, blaOXA-58, blaIMP or blaVIM. In susceptible iso-
lates, only blaOXA-51 was detected.
ISAba1 was detected only upstream of blaOXA-23 in
all isolates.
Isolates were analysed by REP-PCR to determine the
genomic diversity of CRAB. Two genotypes were
observed. The five carbapenem-susceptible control iso-
lates belonged to different genotypes from the CRAB (fig-
ure 1). Genotype A (77.4% of isolates; n = 41) was the
most prevalent and was found in four hospitals, whilst
genotype B (22.6% of isolates; n = 12) had spread in two
hospitals.
Table 1: Susceptibility pattern of 53 imipenem-non-susceptible Acinetobacter baumannii strains to 12 antimicrobial 
agents
Antimicrobial Disk Diffusion
Disc content Zone diameters* (mm) Equivalent MICs 
breakpoints * (mg/l)
Results of disk diffusion n (%)
SRSRSIR
Amikacin 30 μg ≥17 <15 ≤8 >16 25 (47,2) 1 (1,9) 27 (50,9)
Tobramycin 10 μg ≥16 <16 ≤4 >4 36 (67,9) 0 17 (32,1)
Gentamycin 15 μg ≥16 <16 ≤4 >4 1 (1,9) 0 52 (98,1)
Ampicillin/Sulbactam‡ 10 μg/10 μg ≥15 ≤11 ≤8/4 ≥32/16 42 (79.2) 0 11 (20.8)
Ticarcillin/clavulanic acid 75/10 μg ≥22 <18 ≤16/2 >64/2 1 (1,9) 0 52 (98,1)
Piperacilin-Tazobactam 75/10 μg ≥19 <14 ≤16/4 >64/4 0 1 (1,9) 52 (98,1)
Ceftazidime 30 μg ≥21 <19 ≤4 >8 3 (5,7) 0 50 (94,3)
Ciprofloxacin 5 μg ≥22 <19 ≤1 >2 1 (1,9) 0 52 (98,1)
Sulfamethoxazole/
trimethoprim
23.75/1.25 μg ≥16 <13 ≤38/2 >76/4 0 0 53 (100)
Imipenem 10 μg ≥24 <17 ≤2 >8 0 4 (7.5) 49 (92.5)
Colistin 50 μg ≥15 <15 ≤2 >2 53 (100) 0 0
MICs S R MIC50 (mg/l) MIC 90 (mg/l)
Imipenem ≤2 >8 32 32
Meropenem ≤2 >8 ≥32 ≥32
*: According to the Antibiogram Committee of the French Microbiology Society except for Ampicillin/sulbactam
‡: According to the Clinical and Laboratory Standards Institute
S: susceptible; I: intermediate; R: resistant.Andriamanantena et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:17
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4. Discussion
Our study revealed that OXA-23 carbapenemase was
present in A. baumannii isolates in Antananarivo. OXA-
23-type carbapenemase-producing A. baumannii are
becoming increasingly widespread, with reports from
Europe [25-27], South America [9,13,28], or Asia [29-31].
In 2002, 49 strains of imipenem resistant A. baumannii
producing the carbapenenase OXA-23 were isolated in
South Africa [32]. Many strains of OXA-23 producing A.
baumannii from the same clone were responsible for an
epidemic of nocomial infection from 2005 to 2007 in
Tunisia [33].
As in the present study, such isolates usually exhibit
resistance to many antimicrobials, creating a serious
problem for choice of therapy. In our study, patients with
skin infections caused by carbapenem-resistant A. bau-
mannii  received local treatments and most survived
without sequelae. On the contrary, among patients with
urinary, pulmonary or blood stream infections who
received only antibiotics ineffective on the A. baumannii
strains isolated (third generation cephalosporins, cipro-
floxacin or amoxicillin-clavulanic acid), the rate of mor-
tality was high. Indeed 2 of 3 patients with bloodstream
infection, 4 of 8 patients with pulmonary infection and 2
of 10 patients with urinary infection died.
In this study, the OXA-23-producers originated from
two clones. According to Rep-PCR patterns, it appears
that OXA-23-producing CRAB belonging to two pre-
dominant genotypes spread between public and private
hospitals in Antananarivo. Different studies have already
shown that clones of CRAB may spread in a town [13] or
even a country [34]. The occurrence of common Rep-
PCR types in OXA-23-producing A. baumannii from var-
ious hospitals in Antananarivo suggests that dissemina-
tion of isolates contributes to the increase in prevalence
of CRAB. Dissemination of CRAB in the community
could be favoured by poor health facilities and the trans-
fer of infected or colonised patients from a hospital to
another. However, this is rarely the case in Antananarivo.
Sharing of common healthcare staff is more likely. Indeed
staff from public hospitals also works together in the var-
Table 2: Primers used for the detection of carbapenemase genes.
Name Sequence Use Experimental conditions Ref
AmpC 5'- ACTTACTTCAACTCGCGACG -3'
5'- TAAACACCACATATGTTCCG -3'
blaampC Amplification Classical PCR (annealing 
temperature 44°C)
[18]
OXA-51 5'- ATGAACATTAAAGCACTCTTAC -3'
5'- CTATAAAATACCTAATTGTTCT -3'
blaOXA-51 Amplification Classical PCR (annealing 
temperature 50°C)
[19]
OXA-23 5'- GCAAATAMAGAATATGTSCC -3'
5'- CTCMACCCARCCRGTCAACC -3'
blaOXA-23 Amplification & sequencing Classical PCR (annealing 
temperature 58°C)
[20]
OXA-24 5'- GGTTAGTTGGCCCCCTTAAA -3'
5'- AGTTGAGCGAAAAGGGGATT -3'
blaOXA-24 Amplification Classical PCR (annealing 
temperature 59°C)
[21]
VIM 5'- GTTTGGTCGCATATCGCAAC -3'
5'- CTACTCAACGACTGAGCGATTTGT -3'
blaVIM Amplification Classical PCR (annealing 
temperature 60°C)
[13]
IMP 5'- CTACCGCAGCAGAGTCTTTG -3'
5'- AACCAGTTTTGCCTTACCAT -3'
blaIMP Classical PCR (annealing 
temperature 50°C)
[13]
IsAba-1 F/OXA-23 R 5'- CACGAATGCAGAAGTTG - 3'
5'-TTAAATAATATTCAGCTGT - 3'





REP-PCR Amplification Classical PCR (annealing 
temperature 40°C)
[23]
Figure 1 Representative REP-PCR fingerprints of A. baumannii 
isolates from different human samples, corresponding to the dif-
ferent genotypes. Lanes 1 and 17, molecular size marker; lanes 2 to 6, 
genotype A from four hospitals; lanes 7 to 11, genotype B from two 
hospitals; lanes 12 to 16, five carbapeneme susceptible A. baumanii iso-
lates from Antananarivo.
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ious clinics of Madagascar. This hypothesis has already
been evoked to explain the spread of clonal strains
between different hospitals [13,35]. If poor sanitary con-
ditions probably explain how these CRAB clones can
spread, it does not explain how these clones appeared in
Antananarivo. One can suppose that resistant clones
were introduced by patients treated in a developed coun-
try (hospitalization in Reunion Island is rather frequent
for Malagasy patients). However, since carbapenem are
not available in Madagascar, resistance to these drugs
should not confer any advantage to these clones. There-
fore the selection of these clones is probably due to their
resistance to most drugs used in Madagascar than to
resistance to imipenem.
Conclusions
Whatever the reason for this spread, the high level of
CRAB in the hospitals of Antananarivo is a cause for con-
cern as carbapenems are not available in Madagascar.
Thus, the presence of MDR OXA-23 producing A. bau-
mannii genotypes emphasises the need for infection con-
trol procedures and strict adherence to them to prevent
the spread of these resistant organisms in Antananarivo
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